Aravive, Inc. (ARAV)
Jan 29, 2024 - ARAV was delisted (reason: voluntarily delisted)
0.0401
-0.0062 (-13.39%)
Last trade price
Aravive Revenue
Aravive had revenue of $7.00M in the twelve months ending September 30, 2023, down -19.11% year-over-year. Revenue in the quarter ending September 30, 2023 was $2.76M, a -44.39% decrease year-over-year. In the year 2022, Aravive had annual revenue of $9.14M with 22.78% growth.
Revenue (ttm)
$7.00M
Revenue Growth
-19.11%
P/S Ratio
0.42
Revenue / Employee
$304,130
Employees
23
Market Cap
2.95M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 9.14M | 1.70M | 22.78% |
Dec 31, 2021 | 7.44M | 1.76M | 30.91% |
Dec 31, 2020 | 5.69M | 932.00K | 19.61% |
Dec 31, 2019 | 4.75M | 3.38M | 246.68% |
Dec 31, 2018 | 1.37M | -38.63M | -96.57% |
Dec 31, 2017 | 40.00M | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionARAV News
- 3 months ago - Aravive, Inc. to Delist from The Nasdaq Stock Market - GlobeNewsWire
- 9 months ago - Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer - GlobeNewsWire
- 10 months ago - Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023 - GlobeNewsWire
- 10 months ago - Aravive to Participate in William Blair's Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023 - GlobeNewsWire
- 11 months ago - Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c) - GlobeNewsWire
- 11 months ago - Aravive To Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 1 year ago - Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023 - GlobeNewsWire
- 1 year ago - Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma - GlobeNewsWire